AU2003231564A1 - Formulation containing tetrodotoxin for abstinence and analgecize which is administered through respiratory tract - Google Patents

Formulation containing tetrodotoxin for abstinence and analgecize which is administered through respiratory tract

Info

Publication number
AU2003231564A1
AU2003231564A1 AU2003231564A AU2003231564A AU2003231564A1 AU 2003231564 A1 AU2003231564 A1 AU 2003231564A1 AU 2003231564 A AU2003231564 A AU 2003231564A AU 2003231564 A AU2003231564 A AU 2003231564A AU 2003231564 A1 AU2003231564 A1 AU 2003231564A1
Authority
AU
Australia
Prior art keywords
analgecize
abstinence
administered
respiratory tract
formulation containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003231564A
Inventor
Zhiqiang Huang
Zhuguo Liu
Song Pan
Xinfu Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003231564A1 publication Critical patent/AU2003231564A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003231564A 2002-05-23 2003-05-20 Formulation containing tetrodotoxin for abstinence and analgecize which is administered through respiratory tract Abandoned AU2003231564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN02117928.X 2002-05-23
CNB02117928XA CN100360133C (en) 2002-05-23 2002-05-23 Tetrodotoxin respiratory tract administration prepn. used for giving-up drug and easing pain
PCT/CN2003/000370 WO2003099301A1 (en) 2002-05-23 2003-05-20 Formulation containing tetrodotoxin for abstinence and analgecize which is administered through respiratory tract

Publications (1)

Publication Number Publication Date
AU2003231564A1 true AU2003231564A1 (en) 2003-12-12

Family

ID=29426732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003231564A Abandoned AU2003231564A1 (en) 2002-05-23 2003-05-20 Formulation containing tetrodotoxin for abstinence and analgecize which is administered through respiratory tract

Country Status (3)

Country Link
CN (1) CN100360133C (en)
AU (1) AU2003231564A1 (en)
WO (1) WO2003099301A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1568999A (en) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 Stable freeze dried formulation of spheroidine for medical use
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
CN100367966C (en) * 2004-09-28 2008-02-13 黄致强 Tetrodotoxin oil phase formulation preparation method
CN101352422B (en) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 Tetrodotoxin lyophilized powder formulation for injection and preparation method thereof
CN107349206A (en) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 Application of the tetraodotoxin in treatment novel drug ill symptomses and the pharmaceutical composition relapsed are prepared

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1051706C (en) * 1994-03-17 2000-04-26 南宁枫叶药业有限公司 Amino hydrogenated quinazoline oxazoline compound and derivant thereof are guarded against the new purposes of falling drug dependence
CN1072486C (en) * 1996-09-24 2001-10-10 王维国 Medicament for giving up narcotic drugs and stopping pain and its prepn.
CN1085532C (en) * 1998-06-09 2002-05-29 河北省水产研究所 Medicine for giving up medicinal dependence
CN1203857C (en) * 2000-09-18 2005-06-01 威克斯医药有限公司 Method for localized anesthesia and analgesia

Also Published As

Publication number Publication date
WO2003099301A1 (en) 2003-12-04
CN100360133C (en) 2008-01-09
CN1459286A (en) 2003-12-03

Similar Documents

Publication Publication Date Title
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
EP2281555A3 (en) Once-a-day oxycodone formulations
AU2002342050A1 (en) Anesthesia drug monitor
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
AU2003293345A1 (en) Detection of disordered breathing
HUP0303800A3 (en) Pharmaceuticals and dosage forms of epothilones for oral administration
AU2003213020A1 (en) Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
AU2002316771A1 (en) Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
AU2003228967A1 (en) Medicament respiratory delivery device and cartridge
AU2003243439A1 (en) Medical device for intra-lumenal delivery of pharmaceutical agents
AU2003208761A1 (en) A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
EP1686960A4 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
AU2002346143A1 (en) Compositions for nasal administration of insulin
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
AU2003231564A1 (en) Formulation containing tetrodotoxin for abstinence and analgecize which is administered through respiratory tract
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
ZA200500556B (en) The pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof
AU2002237400A1 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
AU2003262229A1 (en) Preventive and/or therapeutic drugs for asthma
AU2002363800A1 (en) Therapeutic agent composition and method of use
GB0113066D0 (en) A method of medicine administration for respiratory tract
AUPR916301A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU2002333157A1 (en) Compound for treatment of anxiety and methods of preparation and use thereof
AU2001274236A1 (en) Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase